Transgender hormone therapy (male-to-female) medical professional. Inducers of CYP3A4 and other cytochrome P450 enzymes can reduce the effects of MTF HRT. A variety of different sex-hormonal medications are used in feminizing hormone therapy for transgender women. These include estrogens to induce feminization and suppress testosterone levels; antiandrogens such as androgen receptor antagonists, antigonadotropins, GnRH modulators, and 5α-reductase inhibitors to further oppose the effects of androgens like testosterone; and progestogens for various possible though uncertain benefits. Estrogens are the major sex hormones in women, and are responsible for the development and maintenance of feminine secondary sexual characteristics, such as breasts, wide hips, and a feminine
Body odour and sexual attraction psychological studies that women’s preferences for various male traits change throughout the menstrual cycle. Hormonal fluctuation across the menstrual cycle explains temporal variation in women’s judgment of the attractiveness of members of the opposite sex. This is due to the psychological processes that shape the formation and maintenance of human romantic relationships are influenced by variation in hormonal levels. Due to their high hormone content, oral contraceptives have the potential to alter women’s partner preference for a range of male traits, which could have important consequences on sexual relationships, as it alters women’s attraction to their partner and, potentially, to